Balaji Amines Limited, a prominent manufacturer of aliphatic amines and speciality chemicals in India, has announced its audited financial results for the quarter and year ended 31st March 2026. The company reported a consolidated revenue of ₹ 403 crore for Q4FY26, marking an increase from ₹ 361 crore in the previous quarter.
The company’s EBITDA for the fourth quarter stood at ₹ 102 crore, compared to ₹ 68 crore in Q4FY25, demonstrating a notable improvement in operational efficiency. The EBITDA margin for the quarter was 25%, up from 19% in the same period last year.
Net profit for Q4FY26 was reported at ₹ 65 crore, reflecting a significant rise from ₹ 40 crore in Q4FY25. The diluted earnings per share (EPS) for the quarter was ₹ 19.99, compared to ₹ 9.49 in the preceding quarter.
Balaji Amines also highlighted its zero-debt status on a standalone basis, showcasing its strong financial health.
The company is advancing several new projects, including the commissioning of a DME plant at Unit-IV in the first quarter of FY 2026-27, and an N-Methyl Morpholine (NMM) plant expected to be operational within the fiscal year. Additionally, an improved process-based acetonitrile plant is anticipated to commence operations in the second quarter of FY 2026-27.
In terms of expansion, Balaji Speciality Chemicals Limited, a subsidiary of Balaji Amines, is investing ₹ 750 crore in a range of products, including hydrogen cyanide and sodium cyanide. The expansion project has been granted Mega Project status by the Government of Maharashtra.
Mr. D. Ram Reddy, Managing Director of Balaji Amines, commented on the company’s resilience in maintaining stable operations despite external disruptions in March 2026. The company’s integrated manufacturing model and execution capabilities have been pivotal in mitigating near-term volatility.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).